Stevanato Group Q4 Earnings Call Highlights

Core Insights - Stevanato Group reported solid financial results for Q4 and fiscal 2025, with significant growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and high-value products related to GLP-1 therapies driving revenue and margin expansion [4][3][7] Financial Performance - Q4 total revenue increased by 7% at constant currency to EUR 346.5 million, with BDS revenue up 13% and engineering revenue down 23% [2] - For fiscal 2025, total revenue rose 9% at constant currency, with High-Value Solutions growing 29% and contributing to a 160 basis points gross margin expansion [3][7] - Adjusted EBITDA for Q4 was EUR 97.7 million, with an adjusted EBITDA margin of 28.2% [7] Segment Performance - BDS segment showed double-digit growth, while engineering faced a decline due to lower order intake [3][21] - High-Value Solutions accounted for approximately 49% of total revenue in Q4 and 46% for the fiscal year [2][3] GLP-1 Exposure - GLP-1-related sales represented about 19-20% of total revenue in 2025, growing over 50% year-over-year, with expectations for mid-teens growth in 2026 [6][8] - The Nexa syringe was highlighted as the fastest-growing product, but capacity constraints are anticipated to persist into 2026 [8][10] Capacity and Investment - The company is ramping up capacity in its Latina and Fishers facilities, with significant investments planned for 2026 to meet rising demand [13][14] - CapEx for 2026 is projected between EUR 270 million to EUR 290 million, with a focus on growth projects [22] Guidance for 2026 - Stevanato expects revenue of EUR 1.26–1.29 billion and adjusted EBITDA of EUR 331.8–346.9 million for 2026, with a forecasted tax rate of approximately 26.8% [5][27] - The company anticipates stronger revenue in the second half of 2026 compared to the first half, with BDS growth expected to be in the high single- to low double-digits [21][22] Operational Improvements - The engineering segment has seen operational enhancements, but revenue is expected to decline in 2026 due to slower order conversion [16][17] - Management noted that site acceptance rates have improved significantly, indicating better execution in engineering projects [16]